Coherus Oncology Reports Q3 2026 Results: Revenue of $14. ...
Non-GAAP Loss Per Share of $0.20 Beats Estimated $0.24 Loss; Revenue of $14.3 Million Trails $16.00 Million Consensus Related Stocks: CHRS ,
Non-GAAP Loss Per Share of $0.20 Beats Estimated $0.24 Loss; Revenue of $14.3 Million Trails $16.00 Million Consensus Related Stocks: CHRS ,